BETHESDA, Md., May 18, 2017 /PRNewswire-USNewswire/ -- Currently, there is a lack of easily accessible and accurate information available to inflammatory bowel disease (IBD) patients of childbearing age about the risks of and opportunities for starting a family. The American Gastroenterological Association (AGA) recognizes the need for patients, their partners and health-care practitioners to have effective conversations about pre-conception, prenatal and post-partum care.
"AGA is committed to helping health-care providers and their patients come together with the goal of high-quality care and to encourage meaningful dialogue about the issues of concern to patients," said Sumner Bell, MD, AGAF, AGA patient education advisor. "AGA is pleased to have been awarded a grant from UCB that will allow us to work with health-care professional and patient advocacy organizations to conduct research, build consensus and disseminate education to IBD patients who are interested in having a family, but who may not be aware of all of the options available to them."
Through this campaign, AGA hopes to help create productive, open discussions between practitioners and people with IBD about options for child bearing, and to remove fears and replace them with facts. Additionally, we will create evidence-based recommendations for health-care professionals who care for women with IBD to ensure continuity of information sharing across GIs and other health-care practitioners for care for these patients.
About the AGA Institute The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization.www.gastro.org.
Like AGA on Facebook. Join AGA on LinkedIn.Follow us on Twitter @AmerGastroAssn. Check out our videos on YouTube.
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Advertisement
"AGA is committed to helping health-care providers and their patients come together with the goal of high-quality care and to encourage meaningful dialogue about the issues of concern to patients," said Sumner Bell, MD, AGAF, AGA patient education advisor. "AGA is pleased to have been awarded a grant from UCB that will allow us to work with health-care professional and patient advocacy organizations to conduct research, build consensus and disseminate education to IBD patients who are interested in having a family, but who may not be aware of all of the options available to them."
Advertisement
Through this campaign, AGA hopes to help create productive, open discussions between practitioners and people with IBD about options for child bearing, and to remove fears and replace them with facts. Additionally, we will create evidence-based recommendations for health-care professionals who care for women with IBD to ensure continuity of information sharing across GIs and other health-care practitioners for care for these patients.
About the AGA Institute The American Gastroenterological Association is the trusted voice of the GI community. Founded in 1897, the AGA has grown to more than 16,000 members from around the globe who are involved in all aspects of the science, practice and advancement of gastroenterology. The AGA Institute administers the practice, research and educational programs of the organization.www.gastro.org.
Like AGA on Facebook. Join AGA on LinkedIn.Follow us on Twitter @AmerGastroAssn. Check out our videos on YouTube.
About UCBUCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.2 billion in 2016. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aga-campaign-to-raise-awareness-of-inflammatory-bowel-disease-in-patients-of-child-bearing-years-300460128.html
SOURCE American Gastroenterological Association
